以åã«ãã«ã¯ã³ãã«ãããé匷åãããè±æåã®è²§è¡çç¶ãžã®åœ±é¿ã玹ä»ããŸããããä»åã¯ãã¡ãã·ã³ã§ã®äºäŸã§ãã
åãããBiofortificationïŒçç©åŠçæ é€åŒ·åïŒçµ¡ã¿ã®ç ç©¶ã
ã«ã¯ã³ããšå€§ããç°ãªãç¹ã¯ã察象ãåäŸéã§ãããšããç¹ã
éã®æ¬ ä¹ç¶æ³ãç°ãªãã§ãããã
ãŸãããã¡ãã¯ãå¯Ÿç §ãæ®éã®è±ïŒéã®é匷åè±ïŒãšãããããã«ãã©ã€ã³ãã§ãã
çµæãšããŠã矀éã§ã¯ææå·®ã瀺ãããªãã£ãããã§ãã
被éšé£åãšå¯Ÿç §é£åã®çŸ€éã§ææå·®ã瀺ãããªãã£ãçµæãšããŠã¯ã以äžã®ãããªçç±ãèããããã§ãããã
ãããèžãŸããŠãããå°ããèå¯ããŠã¿ãŸãã
被éšè ã®ç·ã®åãæçµãå§ãŸãåã®å¥³ã®åã¯ã鿬 ä¹ãèµ·ããã«ããã§ãã
鿬 ä¹ã®æ°å€ã§è²§è¡ç¶æ³ã衚ããŠãã被éšè ãæçµããã女ã®åã«éå®ããé局解æã宿œããã°ã矀éã§ãææå·®ãåºãå¯èœæ§ã¯é«ãã§ãã
远å ã§åè§£æããŠãåå ±åããŠããããããã®ã§ãã
ãŸããçæ³ã¯ãå°åŠçã§ã¯ãªããäžåŠçã§è¡ãã¹ãã ã£ãã®ã§ãããã
äžæ¹ãåäŸéã®æ é€åé¡ãšãã芳ç¹ã§ã¯ãå°åŠçã§è¡ãããè² ããªãã£ãã®ã§ãããã
ãŸããé匷åããŠããªããŠããè±ã«ã¯ããã§ãªãã³éã嫿ããŠããŠãéãè£ããŸãããããŠã鿬 ä¹ç¶æ³ã§ããã°ãå°ãªãéã§ãã£ãŠããéãå¹ççã«åžåãããŸãã
ãã®ãããå¯Ÿç §é£å矀ã§ããæ¬ ä¹ç¶æ ãæ¹åãããã®ãšæšæž¬ãããŸãã
ããšãè±ã«å«ãŸããŠããéã¯ããã§ãªãã³éã§ãããèª¿çæ¹æ³ã«ãã£ãŠããšã³ããµã€ããŒã·ã¹ã§ã®åžåæ§ãäœäžããŠããŸããŸããé·æéãã€ãã€äŒŒã¡ãããšãéã®åžåæ§ã¯èœã¡ãã§ãããã
ãŸããéãæ¬ ä¹ããŠããã°ãåè§£ããŠãåžåãããã®ã§ã倧ããªåœ±é¿ã¯ãªããšãèããããŸããã»ã»ã»ã
äœãã«ããŠããå°ã å¿äœãªããªããšæãããããªå ±åã§ããã
ç¹°ãè¿ããŸãããæ¯éãé局解æããŠãåå ±åããŠããããããã®ã§ãã
ã§ããã»ããšãéã®è©Šéšã£ãŠé£ããã
女æ§ã®è¢«éšè ã®å Žåãæçµåšæãå å³ããªããšãäœãè©äŸ¡ããŠãããå šãããããªããªãã
ã ã£ãŠãæçµäžã¯ãã§ãªãã³ã20ïœ30ïŒ ãèœã¡ããã ããããã®å€åã¯éåžžã«å€§ããã
äºå®ããŠããæã ã®è©Šéšã§ãã鿬 ä¹ã®å¥³æ§ã«éå®ããŠæçµåšæãå å³ããŠããæ®æ®µã®é£äºããéãè£ã£ãŠããŸããããå¯Ÿç §é£åã§ã鿬 ä¹ç¶æ ãå埩ããŠããŸããŸãã
ãã®äžã§ãææå·®ãåºããŠããããšã¯ãéåžžã«å€§å€ãªããšããã¯ããé局解æãå¿ èŠã«ãªã£ãŠããã§ãããã
é 匵ã£ãŠãè¯ãå ±åãã§ããã°ãªããšæããŸãã
åãããBiofortificationïŒçç©åŠçæ é€åŒ·åïŒçµ¡ã¿ã®ç ç©¶ã
ã«ã¯ã³ããšå€§ããç°ãªãç¹ã¯ã察象ãåäŸéã§ãããšããç¹ã
éã®æ¬ ä¹ç¶æ³ãç°ãªãã§ãããã
ãŸãããã¡ãã¯ãå¯Ÿç §ãæ®éã®è±ïŒéã®é匷åè±ïŒãšãããããã«ãã©ã€ã³ãã§ãã
çµæãšããŠã矀éã§ã¯ææå·®ã瀺ãããªãã£ãããã§ãã
A Randomized Feeding Trial of Iron-Biofortified Beans on School Children in Mexico
Abstract
Iron deficiency is a major public health problem worldwide, with the highest burden among children. The objective of this randomized efficacy feeding trial was to determine the effects of consuming iron-biofortified beans (Fe-Beans) on the iron status in children, compared to control beans (Control-Beans). A cluster-randomized trial of biofortified beans (Phaseolus vulgaris L), bred to enhance iron content, was conducted over 6 months. The participants were school-aged children (n = 574; 5â»12 years), attending 20 rural public boarding schools in the Mexican state of Oaxaca. Double-blind randomization was conducted at the school level; 20 schools were randomized to receive either Fe-Beans (n = 10 schools, n = 304 students) or Control-Beans (n = 10 schools, n = 366 students). School administrators, children, and research and laboratory staff were blinded to the intervention group. Iron status (hemoglobin (Hb), serum ferritin (SF), soluble transferrin receptor (sTfR), total body iron (TBI), inflammatory biomarkers C-reactive protein (CRP) and -1-acid glycoprotein (AGP)), and anthropometric indices for individuals were evaluated at the enrollment and at the end of the trial. The hemoglobin concentrations were adjusted for altitude, and anemia was defined in accordance with age-specific World Health Organization (WHO) criteria (i.e., Hb <115 g/L for <12 years and Hb <120 g/L for 12 years). Serum ferritin concentrations were adjusted for inflammation using BRINDA methods, and iron deficiency was defined as serum ferritin at less than 15.0 µg/L. Total body iron was calculated using Cook's equation. Mixed models were used to examine the effects of Fe-Beans on hematological outcomes, compared to Control-Beans, adjusting for the baseline indicator, with school as a random effect. An analysis was conducted in 10 schools (n = 269 students) in the Fe-Beans group and in 10 schools (n = 305 students) in the Control-Beans group that completed the follow-up. At baseline, 17.8% of the children were anemic and 11.3% were iron deficient (15.9%, BRINDA-adjusted). A total of 6.3% of children had elevated CRP (>5.0 mg/L), and 11.6% had elevated AGP (>1.0 g/L) concentrations at baseline. During the 104 days when feeding was monitored, the total mean individual iron intake from the study beans (Fe-bean group) was 504 mg (IQR: 352, 616) over 68 mean feeding days, and 295 mg (IQR: 197, 341) over 67 mean feeding days in the control group (p < 0.01). During the cluster-randomized efficacy trial, indicators of iron status, including hemoglobin, serum ferritin, soluble transferrin receptor, and total body iron concentrations improved from the baseline to endline (6 months) in both the intervention and control groups. However, Fe-Beans did not significantly improve the iron status indicators, compared to Control-Beans. Similarly, there were no significant effects of Fe-Beans on dichotomous outcomes, including anemia and iron deficiency, compared to Control-Beans. In this 6-month cluster-randomized efficacy trial of iron-biofortified beans in school children in Mexico, indicators of iron status improved in both the intervention and control groups. However, there were no significant effects of Fe-Beans on iron biomarkers, compared to Control-Beans. This trial was registered at clinicaltrials.gov as NCT03835377.
Nutrients. 2019;11(2):381.
ãâãGoogle翻蚳
ã¡ãã·ã³ã®åŠç«¥ã察象ãšããéãã€ãªåŒ·åè±ã®ã©ã³ãã 忝èŒè©Šéš
èŠæš
鿬 ä¹çã¯äžçäžã®äž»èŠãªå ¬è¡è¡çåé¡ã§ãããåäŸãã¡ã®éã§æã倧ããªè² æ ãšãªã£ãŠããŸãããã®ç¡äœçºåæå¹æ§æé£è©Šéšã®ç®çã¯ãå¯Ÿç §è±ïŒControl-BeansïŒãšæ¯èŒããŠãé匷åè±ïŒFe-BeansïŒã®æåãåäŸã®éã®ç¶æ ã«åãŒã圱é¿ã調ã¹ãããšã§ãããé嫿éãé«ããããã«è²ãŠããããã€ãªåŒ·åè±ïŒPhaseolus vulgaris LïŒã®ã¯ã©ã¹ã¿ãŒã©ã³ãã å詊éšã6ãæã«ããã£ãŠå®æœãããŸãããåå è ã¯åŠéœ¢æã®åäŸïŒn = 574;5â»12æ³ïŒã§ãã¡ãã·ã³ã®ãªã¢ãã«å·ã«ãã20ã®å°æ¹å ¬ç«å¯å®¿åŠæ ¡ã«éã£ãŠããŸãããäºéç²æ€ç¡äœçºåã¯åŠæ ¡ã¬ãã«ã§å®æœãããŸããã 20ã®åŠæ ¡ãã©ã³ãã åãããŠFe-BeansïŒn = 10åŠæ ¡ãn = 304人ã®åŠçïŒãŸãã¯Control-BeansïŒn = 10åŠæ ¡ãn = 366人ã®åŠçïŒã®ãããããåãåããŸãããåŠæ ¡ã®ç®¡çè ãåäŸãç ç©¶ããã³å®éšå®€ã®ã¹ã¿ããã¯ä»å ¥ã°ã«ãŒããç¥ããããŠããŸããã§ãããéã®ç¶æ ïŒãã¢ã°ããã³ïŒHbïŒãè¡æž ãã§ãªãã³ïŒSFïŒã坿º¶æ§ãã©ã³ã¹ãã§ãªã³å容äœïŒsTfRïŒãå šèº«éïŒTBIïŒãççæ§ãã€ãªããŒã«ãŒCåå¿æ§ã¿ã³ãã¯è³ªïŒCRPïŒããã³-1-é žæ§ç³ã¿ã³ãã¯è³ªïŒAGPïŒïŒãããã³äººäœæž¬å®åäººã®ææšã¯ãç»é²æãšè©Šéšçµäºæã«è©äŸ¡ãããŸããããã¢ã°ããã³æ¿åºŠã¯é«åºŠã«åãããŠèª¿æŽãããè²§è¡ã¯å¹Žéœ¢å¥ã®äžçä¿å¥æ©é¢ïŒWHOïŒã®åºæºã«åŸã£ãŠå®çŸ©ãããŸããïŒã€ãŸããHb <115 g / LïŒ<12幎ïŒããã³Hb <120 g / LïŒ12幎ïŒïŒãè¡æž ãã§ãªãã³æ¿åºŠã¯BRINDAæ³ã䜿çšããŠççã«åãããŠèª¿æŽããã鿬 ä¹ã¯15.0 µg / Læªæºã®è¡æž ãã§ãªãã³ãšããŠå®çŸ©ãããŸãããå šèº«ã®éã¯ã¯ãã¯ã®åŒã䜿çšããŠèšç®ãããŸãããæ··åã¢ãã«ã䜿çšããŠãè¡æ¶²åŠççµæã«å¯ŸããFe-Beanã®åœ±é¿ã調ã¹ãControl-Beanãšæ¯èŒããŠãããŒã¹ã©ã€ã³ææšã調æŽããåŠæ ¡ãã©ã³ãã ãªåœ±é¿ãšããŠäœ¿çšããŸãããåæã¯ããã©ããŒã¢ãããå®äºããFe-Beansã°ã«ãŒãã®10æ ¡ïŒn = 269人ã®åŠçïŒãšControl-Beansã°ã«ãŒãã®10æ ¡ïŒn = 305人ã®åŠçïŒã§å®æœãããŸãããããŒã¹ã©ã€ã³ã§ã¯ãåäŸã®17.8ïŒ ãè²§è¡ã§ã11.3ïŒ ã鿬 ä¹çã§ããïŒ15.9ïŒ ãBRINDAèª¿æŽæžã¿ïŒãåèš6.3ïŒ ã®åäŸãããŒã¹ã©ã€ã³ã§CRPïŒ> 5.0 mg / LïŒãäžæãã11.6ïŒ ãAGPïŒ> 1.0 g / LïŒæ¿åºŠãäžæããŸãããæé£ãç£èŠãã104æ¥éã§ãç ç©¶è±ïŒFe-beanã°ã«ãŒãïŒããã®åã ã®éæåéã®å¹³åã¯ã68å¹³åæé£æ¥ã§504 mgïŒIQRïŒ352ã616ïŒã295 mgïŒIQRïŒ197ã341ïŒã§ããã ïŒå¯Ÿç §çŸ€ã®å¹³åæé£æ¥æ°ã67æ¥ãè¶ ããïŒp <0.01ïŒãã¯ã©ã¹ã¿ãŒã©ã³ãã åæå¹æ§è©Šéšäžããã¢ã°ããã³ãè¡æž ãã§ãªãã³ã坿º¶æ§ãã©ã³ã¹ãã§ãªã³å容äœãå šèº«ã®éæ¿åºŠãªã©ã®éã®ç¶æ ã®ææšã¯ãä»å ¥çŸ€ãšââå¯Ÿç §çŸ€ã®äž¡æ¹ã§ããŒã¹ã©ã€ã³ãããšã³ãã©ã€ã³ïŒ6ãæïŒãŸã§æ¹åããŸããããã ããFe-Beansã¯ãControl-Beansãšæ¯èŒããŠãéã®ç¶æ ã€ã³ãžã±ãŒã¿ãŒãå€§å¹ ã«æ¹åããŸããã§ãããåæ§ã«ãå¯Ÿç §è±ãšæ¯èŒããŠãè²§è¡ã鿬 ä¹ãªã©ã®äºåãããçµæã«å¯ŸããFeè±ã®ææãªåœ±é¿ã¯ãããŸããã§ãããã¡ãã·ã³ã®åŠç«¥ã察象ãšããéãã€ãªåŒ·åè±ã®ãã®6ãæéã®ã¯ã©ã¹ã¿ãŒã©ã³ãã åæå¹æ§è©Šéšã§ã¯ãä»å ¥çŸ€ãšââå¯Ÿç §çŸ€ã®äž¡æ¹ã§éã®ç¶æ ã®ææšãæ¹åããŸããããã ããControl-Beansãšæ¯èŒããŠãéãã€ãªããŒã«ãŒã«å¯ŸããFe-Beansã®ææãªåœ±é¿ã¯ãããŸããã§ããããã®è©Šéšã¯ãclinicaltrials.govã«NCT03835377ãšããŠç»é²ãããŸããã
被éšé£åãšå¯Ÿç §é£åã®çŸ€éã§ææå·®ã瀺ãããªãã£ãçµæãšããŠã¯ã以äžã®ãããªçç±ãèããããã§ãããã
ãããèžãŸããŠãããå°ããèå¯ããŠã¿ãŸãã
被éšè ã®ç·ã®åãæçµãå§ãŸãåã®å¥³ã®åã¯ã鿬 ä¹ãèµ·ããã«ããã§ãã
鿬 ä¹ã®æ°å€ã§è²§è¡ç¶æ³ã衚ããŠãã被éšè ãæçµããã女ã®åã«éå®ããé局解æã宿œããã°ã矀éã§ãææå·®ãåºãå¯èœæ§ã¯é«ãã§ãã
远å ã§åè§£æããŠãåå ±åããŠããããããã®ã§ãã
ãŸããçæ³ã¯ãå°åŠçã§ã¯ãªããäžåŠçã§è¡ãã¹ãã ã£ãã®ã§ãããã
äžæ¹ãåäŸéã®æ é€åé¡ãšãã芳ç¹ã§ã¯ãå°åŠçã§è¡ãããè² ããªãã£ãã®ã§ãããã
ãŸããé匷åããŠããªããŠããè±ã«ã¯ããã§ãªãã³éã嫿ããŠããŠãéãè£ããŸãããããŠã鿬 ä¹ç¶æ³ã§ããã°ãå°ãªãéã§ãã£ãŠããéãå¹ççã«åžåãããŸãã
ãã®ãããå¯Ÿç §é£å矀ã§ããæ¬ ä¹ç¶æ ãæ¹åãããã®ãšæšæž¬ãããŸãã
ããšãè±ã«å«ãŸããŠããéã¯ããã§ãªãã³éã§ãããèª¿çæ¹æ³ã«ãã£ãŠããšã³ããµã€ããŒã·ã¹ã§ã®åžåæ§ãäœäžããŠããŸããŸããé·æéãã€ãã€äŒŒã¡ãããšãéã®åžåæ§ã¯èœã¡ãã§ãããã
ãŸããéãæ¬ ä¹ããŠããã°ãåè§£ããŠãåžåãããã®ã§ã倧ããªåœ±é¿ã¯ãªããšãèããããŸããã»ã»ã»ã
äœãã«ããŠããå°ã å¿äœãªããªããšæãããããªå ±åã§ããã
ç¹°ãè¿ããŸãããæ¯éãé局解æããŠãåå ±åããŠããããããã®ã§ãã
ã§ããã»ããšãéã®è©Šéšã£ãŠé£ããã
女æ§ã®è¢«éšè ã®å Žåãæçµåšæãå å³ããªããšãäœãè©äŸ¡ããŠãããå šãããããªããªãã
ã ã£ãŠãæçµäžã¯ãã§ãªãã³ã20ïœ30ïŒ ãèœã¡ããã ããããã®å€åã¯éåžžã«å€§ããã
äºå®ããŠããæã ã®è©Šéšã§ãã鿬 ä¹ã®å¥³æ§ã«éå®ããŠæçµåšæãå å³ããŠããæ®æ®µã®é£äºããéãè£ã£ãŠããŸããããå¯Ÿç §é£åã§ã鿬 ä¹ç¶æ ãå埩ããŠããŸããŸãã
ãã®äžã§ãææå·®ãåºããŠããããšã¯ãéåžžã«å€§å€ãªããšããã¯ããé局解æãå¿ èŠã«ãªã£ãŠããã§ãããã
é 匵ã£ãŠãè¯ãå ±åãã§ããã°ãªããšæããŸãã











